Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
作者： Sho-ichi Yamagishi , Kazuo Nakamura , Takanori Matsui , So Ueda , Yoshihiro Noda
DOI: 10.1111/J.1527-3466.2007.00038.X
关键词:
摘要: Accelerated atherosclerosis and microvascular complications are the leading causes of coronary heart disease, stroke, blindness, end-stage renal failure, which could account for disabilities high mortality rates in patients with diabetes. Recent clinical studies have substantiated concept "hyperglycemic memory" pathogenesis cardiovascular disease (CVD) Indeed, Diabetes Control Complications Trial-Epidemiology Interventions (DCCT-EDIC) Research, has revealed that intensive therapy during DCCT reduces risk events by about 50% type 1 diabetic 11 years after end trial. Among various biochemical pathways activated under conditions, process formation accumulation advanced glycation products (AGEs) their mode action most compatible theory memory." Further, there is a growing body evidence AGEs play an important role CVD These observations suggest inhibition may be promising target therapeutic intervention vascular complications. Therefore, this article, we review several agents inhibitory effects on implications
sci-hub.se 参考文章(76)
Bucala R, Vlassara H, Striker L, Pathogenic Effects of Advanced Glycosylation: Biochemical, Biologic, and Clinical Implications for Diabetes and Aging Laboratory Investigation. ,vol. 70, pp. 138- 151 ,(1994)
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. The Lancet. ,vol. 361, pp. 2005- 2016 ,(2003) , 10.1016/S0140-6736(03)13636-7
S.K. Grandhee, V.M. Monnier, Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. Journal of Biological Chemistry. ,vol. 266, pp. 11649- 11653 ,(1991) , 10.1016/S0021-9258(18)99006-X
D.G. Dyer, J.A. Blackledge, S.R. Thorpe, J.W. Baynes, Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. Journal of Biological Chemistry. ,vol. 266, pp. 11654- 11660 ,(1991) , 10.1016/S0021-9258(18)99007-1
Diabetes Control and Complications Trial, None, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine. ,vol. 353, pp. 2643- 2653 ,(2005) , 10.1056/NEJMOA052187
Richard Bucala, Anthony Cerami, None, Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Advances in pharmacology (San Diego). ,vol. 23, pp. 1- 34 ,(1992) , 10.1016/S1054-3589(08)60961-8
Takashi Sato, Noriko Shimogaito, Xuegang Wu, Seiji Kikuchi, Sho-ichi Yamagishi, Masayoshi Takeuchi, Toxic Advanced Glycation End Products (TAGE) Theory in Alzheimer’s Disease American Journal of Alzheimers Disease and Other Dementias. ,vol. 21, pp. 197- 208 ,(2006) , 10.1177/1533317506289277
T. Yoshida, S. Yamagishi, K. Nakamura, T. Matsui, T. Imaizumi, M. Takeuchi, H. Koga, T. Ueno, M. Sata, Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation Diabetologia. ,vol. 49, pp. 3094- 3099 ,(2006) , 10.1007/S00125-006-0437-7
A. Hoang, A. J. Murphy, M. T. Coughlan, M. C. Thomas, J. M. Forbes, R. O’Brien, M. E. Cooper, J. P. F. Chin-Dusting, D. Sviridov, Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties Diabetologia. ,vol. 50, pp. 1770- 1779 ,(2007) , 10.1007/S00125-007-0718-9
K. Shimoi, A. Okitsu, M.H.L. Green, J.E. Lowe, T. Ohta, K. Kaji, H. Terato, H. Ide, N. Kinae, Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells. Mutation Research. ,vol. 480, pp. 371- 378 ,(2001) , 10.1016/S0027-5107(01)00196-8